Skip to content

A prospective cohort study on the treatment of chronic musculoskeletal pain caused by osteoporosis with Jintiange capsules

A prospective cohort study on the treatment of chronic musculoskeletal pain caused by osteoporosis with Jintiange capsules

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
ITMCTR
Registry ID
ITMCTR2100005385
Enrollment
Unknown
Registered
2021-12-08
Start date
2021-12-15
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic pain in the musculoskeletal system caused by osteoporosis

Interventions

The exposed group:Patients who use Xianling Gubao capsule alone, or on the basis of conventional treatment with Western medicine, use Xianling Gubao capsule, and do not use other similar Traditional C
Exposed group:Patients who use Jintiange capsules alone or on the basis of conventional treatment with Western medicine, and do not use other similar Traditional Chinese medicine

Sponsors

The Third Affiliated Hospital of Beijing University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients with chronic musculoskeletal pain caused by osteoporosis who meet the ICD-11 criteria for chronic pain; 2. Patients with 4 =VAS score < 7 at first visit; 3. Patients who meet the diagnostic criteria for TCM diagnosis of kidney deficiency syndrome.

Exclusion criteria

Exclusion criteria: There is no

Design outcomes

Primary

MeasureTime frame
Bone mineral density;;Single symptom score;;Clinical symptom score change value;;VAS score for pain;;Bone conversion markers;;Short Form health Survey (SF-12) score;Total effective rate of clinical symptom score;;Clinical symptom score reduction rate;;

Countries

China

Contacts

Public ContactWei-heng Chen
drchenweiheng@163.com13511013261

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026